PRINCETON, N.J., July 13, 2026
ANI Pharmaceuticals announced positive six-month topline results from the Phase 4, open-label, single-arm SYNCHRONICITY clinical trial evaluating ILUVIEN® (fluocinolone acetonide intravitreal implant 0.18 mg) in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The study successfully achieved both co-primary efficacy endpoints, demonstrating statistically significant improvements in best corrected visual acuity (BCVA) and central subfield thickness (CST) after six months of treatment. Conducted across retina specialty centers in the United States, the trial provides additional real-world clinical evidence supporting ILUVIEN as a long-duration corticosteroid therapy for patients suffering from chronic posterior segment uveitis. According to the company, the findings reinforce ILUVIEN’s established role in controlling chronic ocular inflammation while improving both anatomical and functional vision outcomes in patients routinely treated by retina specialists.
Trial Meets Both Co-Primary Endpoints with Statistically Significant Improvements
The SYNCHRONICITY study enrolled 108 patients with chronic NIU-PS in the intent-to-treat population and demonstrated meaningful improvements across both predefined primary efficacy measures. Patients experienced an average gain of 3.6 ETDRS letters in best corrected visual acuity after six months, improving from a baseline mean score of 62.5 letters to 65.8 letters, achieving statistical significance (p<0.0077). Anatomical improvements were equally notable, with mean central subfield thickness decreasing by 157.5 microns, from 505.7 microns at baseline to 348.8 microns after treatment (p<0.0001). These findings indicate that ILUVIEN not only improves visual function but also substantially reduces retinal inflammation and edema associated with chronic posterior segment uveitis. The company stated that complete clinical results and additional subgroup analyses will be presented during upcoming scientific and ophthalmology conferences later in 2026.
Safety Profile Remains Consistent with Previous ILUVIEN Studies
The safety findings observed during the Phase 4 trial remained consistent with the well-established safety profile previously reported for fluocinolone acetonide intravitreal implants. Treatment-related adverse events occurred in 29% of patients, with the most commonly reported events being ocular hypertension (6%) and cataract (5%). Approximately 18% of patients experienced an increase in intraocular pressure of at least 25 mmHg, while 7% required laser or surgical intervention to lower intraocular pressure. Despite these anticipated corticosteroid-associated ocular events, investigators reported that the overall safety profile aligned closely with previous ILUVIEN clinical studies and remained manageable with appropriate ophthalmic monitoring. The company emphasized that no unexpected safety signals emerged during the study, supporting continued confidence in the long-term safety of the implant when used according to approved prescribing guidelines.
Advertisement
Positive Results Reinforce ILUVIEN’s Role in Chronic Posterior Uveitis Management
The SYNCHRONICITY trial further strengthens ANI Pharmaceuticals’ ophthalmology portfolio by expanding the clinical evidence supporting ILUVIEN in chronic non-infectious posterior segment uveitis. ILUVIEN is a sustained-release intravitreal corticosteroid implant designed to provide continuous fluocinolone acetonide delivery for up to 36 months, reducing the need for frequent retreatment while maintaining long-term inflammatory control. Originally approved by the U.S. Food and Drug Administration for diabetic macular edema, ILUVIEN received expanded FDA labeling in 2025 for chronic NIU-PS following consolidation of its prescribing information. The positive Phase 4 findings demonstrate that treatment with ILUVIEN provides clinically meaningful improvements in both visual acuity and retinal anatomy while maintaining a predictable safety profile in patients managed by retina specialists. ANI Pharmaceuticals stated that these results reinforce its commitment to advancing innovative ophthalmic therapies capable of preserving vision and improving quality of life for patients living with chronic inflammatory eye diseases.
Source: ANI Pharmaceuticals press release
